BioLineRx Ltd.
NASDAQ•BLRX
CEO: Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2011-07-27
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Contact Information
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, 7177871, Israel
972-8-642-9100
Market Cap
$14.66M
P/E (TTM)
-1.6
24.5
Dividend Yield
--
52W High
$5.27
52W Low
$2.15
52W Range
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data